Drug developer ChemoCentryx has priced its IPO in a range of $14-$16, and says it plans to sell...

|By:, SA News Editor

Drug developer ChemoCentryx has priced its IPO in a range of $14-$16, and says it plans to sell 4M shares under the ticker CCXI. ChemoCentryx, which counts GlaxoSmithKline (GSK) among its major shareholders and development partners, generated R&D payment revenue of $5.6M (-74% Y/Y) over the first 9 months of 2011, and a net loss of $22.8M. (S-1 filing)